Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Hargadon, Kristian M ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

Cancer immunotherapy; Dendritic cell; Immune suppression; Immunogenic cell death; Immunometabolism; Melanoma; Microbiome; Tumor

Indexed keywords

CD103 ANTIGEN; CD1C ANTIGEN; CD34 ANTIGEN; CD8ALPHA ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK PROTEIN 90; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAFOSFAMIDE; MITOXANTRONE; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; INTESTINE FLORA; MELANOMA; MONOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SKIN FLORA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 85034618722     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01594     Document Type: Review

References (210)

1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society (2016). p. 1-9
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359-86. doi:10.1002/ijc.29210
3. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al., editors. SEER Cancer Statistics Review 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975-2013 National Cancer Institute. SEER Cancer Stat Rev 1975-2013. Bethesda, MD: Natl Cancer Institute (2016). Available from: http://seer.cancer.gov/csr/1975_2013/
4. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol (2016) 136:1161-71. doi:10.1016/j.jid.2016.01.035
5. Guy GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med (2015) 48:183-7. doi:10.1016/j.amepre.2014.08.036
6. Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer (2013) 132:385-400. doi:10.1002/ijc.27616
7. Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J (2012) 18:176-84. doi:10.1097/PPO.0b013e31824bc981
8. Lejeune FJ. The impact of surgery on the course of melanoma. Recent Results Cancer Res (2002) 160:151-7. doi:10.1007/978-3-642-59410-6_18
9. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 113:2139-45. doi:10.1002/cncr.23805
10. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2008) 26:5748-54. doi:10.1200/JCO.2008.17.5448
11. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 15:323-32. doi:10.1016/S1470-2045(14)70012-9
12. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 380:358-65. doi:10.1016/S0140-6736(12)60868-X
13. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 367:107-14. doi:10.1056/NEJMoa1203421
14. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2014) 4:94-109. doi:10.1158/2159-8290.CD-13-0617
15. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 20:1965-77. doi:10.1158/1078-0432.CCR-13-3122
16. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2013) 31:482-9. doi:10.1200/JCO.2012.43.5966
17. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol (2017) 28:1631-9. doi:10.1093/annonc/mdx176
18. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol (2016) 34:871-8. doi:10.1200/JCO.2015.62.9345
19. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 372:2006-17. doi:10.1056/NEJMoa1414428
20. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 16:375-84. doi:10.1016/S1470-2045(15)70076-8
21. Felix J, Lambert J, Roelens M, Maubec E, Guermouche H, Pages C, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. Oncoimmunology (2016) 5:1136045. doi:10.1080/2162402X.2015.1136045
22. Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 5:1481-91. doi:10.1002/cam4.732
23. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372:2521-32. doi:10.1056/NEJMoa1503093
24. Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol (2016) 34:4102-9. doi:10.1200/JCO.2016.67.2477
25. Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer (2017) 75:47-55. doi:10.1016/j.ejca.2017.01.009
26. Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, et al. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res (2017) 23:5666-70. doi:10.1158/1078-0432.CCR-16-0663
27. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res (2015) 21:712-20. doi:10.1158/1078-0432.CCR-14-2468
28. Coens C, Suciu S, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol (2017) 18:393-403. doi:10.1016/S1470-2045(17)30015-3
29. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol (2016) 27:1492-504. doi:10.1093/annonc/mdw217
30. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17:4550-7. doi:10.1158/1078-0432.CCR-11-0116
31. Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res (2015) 21:1019-27. doi:10.1158/1078-0432.CCR-14-2708
32. Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 21:4016-26. doi:10.1200/JCO.2003.10.005
33. Slingluff CL, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol (2004) 22:4474-85. doi:10.1200/JCO.2004.10.212
34. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 61:6451-8
35. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4:328-32. doi:10.1038/nm0398-328
36. Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 15:7036-44. doi:10.1158/1078-0432.CCR-09-1544
37. Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol (2011) 29:2924-32. doi:10.1200/JCO.2010.33.8053
38. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39:38-48. doi:10.1016/j.immuni.2013.07.004
39. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 15:e257-67. doi:10.1016/S1470-2045(13)70585-0
40. Rodríguez-Cerdeira C, Gregorio MC, López-Barcenas A, Sánchez-Blanco E, Sánchez-Blanco B, Fabbrocini G, et al. Advances in immunotherapy for melanoma: a comprehensive review. Mediators Inflamm (2017) 2017:1-14. doi:10.1155/2017/3264217
41. Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 6:e1328341. doi:10.1080/2162402X.2017.1328341
42. Tel J, Aarntzen EHJG, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 73:1063-75. doi:10.1158/0008-5472.CAN-12-2583
43. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res (2016) 22:2155-66. doi:10.1158/1078-0432.CCR-15-2205
44. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 348:803-8. doi:10.1126/science.aaa3828
45. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature (2017) 547:217-21. doi:10.1038/nature22991
46. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547:222-6. doi:10.1038/nature23003
47. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103 + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity (2016) 44:924-38. doi:10.1016/j.immuni.2016.03.012
48. Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature (2016) 534:396-401. doi:10.1038/nature18300
49. Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol (2017) 38:577-93. doi:10.1016/j.it.2017.05.006
50. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev (2009) 227:234-47. doi:10.1111/j.1600-065X.2008.00718.x
51. Janeway CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today (1992) 13:11-6. doi:10.1016/0167-5699(92)90198-G
52. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.iy.12.040194.005015
53. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2017) 17:97-111. doi:10.1038/nri.2016.107
54. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (2015) 350:972-8. doi:10.1126/science.aad0779
55. Weyd H, Abeler-Dörner L, Linke B, Mahr A, Jahndel V, Pfrang S, et al. Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity. PLoS One (2013) 8:e62449. doi:10.1371/journal.pone.0062449
56. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med (2014) 20:1301-9. doi:10.1038/nm.3708
57. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood (2007) 109:4839-45. doi:10.1182/blood-2006-10-054221
58. Tsang YW, Huang CC, Yang KL, Chi MS, Chiang HC, Wang YS, et al. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy. BMC Cancer (2015) 15:708. doi:10.1186/s12885-015-1690-2
59. Ji J, Fan Z, Zhou F, Wang X, Shi L, Zhang H, et al. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget (2015) 6:17135-46. doi:10.18632/oncotarget.3529
60. Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med (2016) 8:328ra27. doi:10.1126/scitranslmed.aae0105
61. Mikyšková R, Štepánek I, Indrová M, Bieblová J, Šímová J, Truxová I, et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol (2016) 48:953-64. doi:10.3892/ijo.2015.3314
62. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 4:e1008866. doi:10.1080/2162402X.2015.1008866
63. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev (2007) 33:665-80. doi:10.1016/j.ctrv.2007.06.004
64. Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 124:130-9. doi:10.1002/ijc.23886
65. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-A-specific, tumor-reactive CTL in melanoma patients. Cancer Res (2010) 70:7084-92. doi:10.1158/0008-5472.CAN-10-1326
66. Michaud M, Xie X, Bravo-San Pedro JM, Zitvogel L, White E, Kroemer G. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology (2014) 3:e944047. doi:10.4161/21624011.2014.944047
67. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 202:1691-701. doi:10.1084/jem.20050915
68. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat Med (2009) 15:1170-8. doi:10.1038/nm.2028
69. Rodríguez-Salazar MDC, Franco-Molina MA, Mendoza-Gamboa E, Martínez-Torres AC, Zapata-Benavides P, López-González JS, et al. The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncol Lett (2017) 14:844-52. doi:10.3892/ol.2017.6202
70. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res (2015) 75:1603-14. doi:10.1158/0008-5472.CAN-14-2089
71. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2011) 71:768-78. doi:10.1158/0008-5472.CAN-10-2788
72. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol (2013) 133:1610-9. doi:10.1038/jid.2012.444
73. Rossowska J, Pajtasz-Piasecka E, Anger N, Wojas-Turek J, Kicielinska J, Piasecki E, et al. Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number. J Immunother (2014) 37:427-39. doi:10.1097/CJI.0000000000000054
74. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, et al. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother (2012) 61:1791-804. doi:10.1007/s00262-012-1242-4
75. Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, et al. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med (2015) 13:139. doi:10.1186/s12967-015-0473-5
76. Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother (2014) 63:601-13. doi:10.1007/s00262-014-1540-0
77. Eike LM, Mauseth B, Camilio KA, Rekdal Ø, Sveinbjørnsson B. The Cytolytic amphipathic β(2,2)-amino acid LTX-401 induces DAMP release in melanoma cells and causes complete regression of B16 melanoma. PLoS One (2016) 11:e0148980. doi:10.1371/journal.pone.0148980
78. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2013) 20:7-15. doi:10.1038/gt.2011.205
79. Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, et al. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther (2017) 10:2389-401. doi:10.2147/OTT.S126320
80. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 15:1257-70. doi:10.1038/gt.2008.58
81. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther (2011) 19:1558-68. doi:10.1038/mt.2011.29
82. Martin S, Dudek-Peric AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S, et al. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochem Pharmacol (2015) 93:290-304. doi:10.1016/j.bcp.2014.12.003
83. Adkins I, Fucikova J, Garg AD, Agostinis P, Špíšek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 3:e968434. doi:10.4161/21624011.2014.968434
84. Khan M, Almasan N, Almasan A, Macklis R. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 4:137. doi:10.2147/OTT.S20257
85. Huang YY, Vecchio D, Avci P, Yin R, Garcia-Diaz M, Hamblin MR. Melanoma resistance to photodynamic therapy: new insights. Biol Chem (2013) 394:239-50. doi:10.1515/hsz-2012-0228
86. Sharma KV, Davids LM. Depigmentation in melanomas increases the efficacy of hypericin-mediated photodynamic-induced cell death. Photodiagnosis Photodyn Ther (2012) 9:156-63. doi:10.1016/j.pdpdt.2011.09.003
87. Hargadon KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 4:192. doi:10.3389/fimmu.2013.00192
88. Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H, Hiddingh L, et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology (2012) 1:649-58. doi:10.4161/onci.20365
89. Sombroek CC, Stam AGM, Masterson AJ, Lougheed SM, Schakel MJAG, Meijer CJLM, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 168:4333-43. doi:10.4049/jimmunol.168.9.4333
90. Péguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol (2003) 170:3488-94. doi:10.4049/jimmunol.170.7.3488
91. Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Péguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol (2006) 18:879-86. doi:10.1093/intimm/dxl024
92. Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H, Waite JC, et al. Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nat Commun (2015) 6:6840. doi:10.1038/ncomms7840
93. Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, et al. Melanoma-educated CD14 + cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 73:3877-87. doi:10.1158/0008-5472.CAN-12-4115
94. Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, et al. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res (2012) 25:493-505. doi:10.1111/j.1755-148X.2012.01005.x
95. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol (2004) 165:1853-63. doi:10.1016/S0002-9440(10)63238-5
96. Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, et al. Functional characterization of a STAT3-dependent dendritic cell-derived CD14 + cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 2:e23837. doi:10.4161/onci.23837
97. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, et al. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res (2011) 17:7230-9. doi:10.1158/1078-0432.CCR-11-1354
98. Tham M, Wai Tan K, Keeble J, Wang X, Hubert S, Barron L, et al. Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget (2014) 5:12027-42. doi:10.18632/oncotarget.2482
99. Hargadon KM, Bishop JD, Brandt JP, Hand ZC, Ararso YT, Forrest OA. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol Cell Biol (2016) 94:24-38. doi:10.1038/icb.2015.58
100. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 56:1459-69. doi:10.1007/s00262-007-0286-3
101. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, et al. Selective accumulation of mature DC-lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 64:2192-8. doi:10.1158/0008-5472.CAN-03-2969
102. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 13:3825-30. doi:10.1158/1078-0432.CCR-07-0358
103. Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother (2008) 57:1665-73. doi:10.1007/s00262-008-0487-4
104. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 200:255-68. doi:10.1002/path.1344
105. Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol (2009) 182:2726-37. doi:10.4049/jimmunol.0803479
106. Ataera H, Hyde E, Price KM, Stoitzner P, Ronchese F. Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4+CD25+ regulatory T cells. PLoS One (2011) 6:e17515. doi:10.1371/journal.pone.0017515
107. Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, et al. Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother (2013) 62:811-22. doi:10.1007/s00262-012-1389-z
108. Jackson AM, Mulcahy LA, Zhu XW, O'Donnell D, Patel PM. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer (2008) 123:623-32. doi:10.1002/ijc.23530
109. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer (1997) 73:309-16. doi:10.1002/(SICI)1097-0215(19971104)73:3<309:AID-IJC1>3.0.CO;2-3
110. Hargadon KM, Forrest OA, Reddy PR. Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors. Cell Immunol (2012) 272:275-82. doi:10.1016/j.cellimm.2011.10.003
111. Hargadon KM, Ararso YT, Forrest OA, Harte CM. Melanoma-associated suppression of the dendritic cell lines DC2.4 and JAWSII. Am J Immunol (2012) 8:179-90. doi:10.3844/ajisp.2012.179.190
112. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 196:541-9. doi:10.1084/jem.20020732
113. Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell (2015) 162:1257-70. doi:10.1016/j.cell.2015.08.015
114. Jiang A, Bloom O, Ono S, Cui W, Unternaehrer J, Jiang S, et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity (2007) 27:610-24. doi:10.1016/j.immuni.2007.08.015
115. Liang X, Fu C, Cui W, Ober-Blobaum JL, Zahner SP, Shrikant PA, et al. β-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8+ T cells. J Leukoc Biol (2014) 95:179-90. doi:10.1189/jlb.0613330
116. Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol (2011) 187:27-36. doi:10.4049/jimmunol.1002067
117. Liu L, Yi H, Wang C, He H, Li P, Pan H, et al. Integrated nanovaccine with microRNA-148a inhibition reprograms tumor-associated dendritic cells by modulating miR-148a/DNMT1/SOCS1 axis. J Immunol (2016) 197:1231-41. doi:10.4049/jimmunol.1600182
118. Fainaru O, Almog N, Yung CW, Nakai K, Montoya-Zavala M, Abdollahi A, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J (2010) 24:1411-8. doi:10.1096/fj.09-147025
119. Xia S, Wei J, Wang J, Sun H, Zheng W, Li Y, et al. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. J Leukoc Biol (2014) 95:733-42. doi:10.1189/jlb.0713371
120. Hong Y, Manoharan I, Suryawanshi A, Majumdar T, Angus-Hill ML, Koni PA, et al. β-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res (2015) 75:656-65. doi:10.1158/0008-5472.CAN-14-2377
121. Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS, et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res (2015) 3:1082-95. doi:10.1158/2326-6066.CIR-14-0167
122. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-educated CD11bhigh Ialow regulatory dendritic cells suppress T cell response through arginase I. J Immunol (2009) 182:6207-16. doi:10.4049/jimmunol.0803926
123. Mahadevan NR, Anufreichik V, Rodvold JJ, Chiu KT, Sepulveda H, Zanetti M. Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8+ T cell priming. PLoS One (2012) 7:e51845. doi:10.1371/journal.pone.0051845
124. Nakahara T, Oba J, Shimomura C, Kido-Nakahara M, Furue M. Early tumor-infiltrating dendritic cells change their characteristics drastically in association with murine melanoma progression. J Invest Dermatol (2016) 136:146-53. doi:10.1038/JID.2015.359
125. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol (2012) 189:2110-7. doi:10.4049/jimmunol.1102282
126. Zhao F, Falk C, Osen W, Kato M, Schadendorf D, Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 15:4382-90. doi:10.1158/1078-0432.CCR-09-0399
127. Tang M, Diao J, Gu H, Khatri I, Zhao J, Cattral MS. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep (2015) 13:2851-64. doi:10.1016/j.celrep.2015.11.053
128. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 202:919-29. doi:10.1084/jem.20050463
129. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 114:280-90. doi:10.1172/JCI21583
130. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 113:6102-11. doi:10.1182/blood-2008-12-195354
131. Aspord C, Leccia MT, Charles J, Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res (2013) 1:402-15. doi:10.1158/2326-6066.CIR-13-0114-T
132. Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov (2016) 6:71-9. doi:10.1158/2159-8290.CD-15-0510
133. Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, et al. Temporally programmed CD8a(+) DC activation enhances combination cancer immunotherapy. Cell Rep (2016) 17:2503-11. doi:10.1016/j.celrep.2016.11.020
134. Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141+ dendritic cells and enhanced cross-presentation. Cancer Immunol Res (2015) 3:495-505. doi:10.1158/2326-6066.CIR-14-0165
135. van den Hout MFCM, Sluijter BJR, Santegoets SJAM, van Leeuwen PAM, van den Tol MP, van den Eertwegh AJM, et al. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node. Cancer Immunol Immunother (2016) 65:405-15. doi:10.1007/s00262-016-1811-z
136. Chen D, Koropatnick J, Jiang N, Zheng X, Zhang X, Wang H, et al. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes. J Immunother (2014) 37:123-34. doi:10.1097/CJI.0000000000000022
137. Bhanumathy K, Zhang B, Ahmed K, Qureshi M, Xie Y, Tao M, et al. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory t cell suppression via IL-6-induced Foxp3 downregulation. Int J Mol Sci (2014) 15:5508-21. doi:10.3390/ijms15045508
138. Aravindaram K, Wang PH, Yin SY, Yang NS. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Gene Ther (2014) 21:457-67. doi:10.1038/gt.2014.12
139. Conroy H, Galvin KC, Higgins SC, Mills KHG. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother (2012) 61:425-31. doi:10.1007/s00262-011-1188-y
140. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 22:1546-53. doi:10.1038/nbt1035
141. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 116:90-100. doi:10.1172/JCI26169
142. Zheng X, Zhang X, Vladau C, Li M, Suzuki M, Chen D, et al. A novel immune-based cancer therapy using gene-silenced dendritic cells (48.8). J Immunol (2007) 178(1 Suppl):S76
143. Sioud M, Nyakas M, Saebøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G. Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine. Case Rep Med (2016) 2016:1-7. doi:10.1155/2016/9639585
144. Chhabra A, Chakraborty NG, Mukherji B. Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin Immunol (2008) 126:251-9. doi:10.1016/j.clim.2007.11.011
145. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 115:4742-9. doi:10.1182/blood-2009-10-249540
146. Everts B, Amiel E, Huang SC, Smith AM, Chang CH, Lam WY, et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKK supports the anabolic demands of dendritic cell activation. Nat Immunol (2014) 15:323-32. doi:10.1038/ni.2833
147. Everts B, Amiel E, van der Windt GJW, Freitas TC, Chott R, Yarasheski KE, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood (2012) 120:1422-31. doi:10.1182/blood-2012-03-419747
148. Pantel A, Teixeira A, Haddad E, Wood EG, Steinman RM, Longhi MP. Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol (2014) 12:e1001759. doi:10.1371/journal.pbio.1001759
149. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv (2016) 2:e1600200. doi:10.1126/sciadv.1600200
150. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab (2016) 23:27-47. doi:10.1016/j.cmet.2015.12.006
151. Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, et al. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol (2017) 8:248. doi:10.3389/fimmu.2017.00248
152. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell (2013) 23:302-15. doi:10.1016/j.ccr.2013.02.003
153. Laurenzana A, Chillà A, Luciani C, Peppicelli S, Biagioni A, Bianchini F, et al. uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells. Int J Cancer (2017) 141:1190-200. doi:10.1002/ijc.30817
154. Ratnikov BI, Scott DA, Osterman AL, Smith JW, Ronai ZA. Metabolic rewiring in melanoma. Oncogene (2017) 36:147-57. doi:10.1038/onc.2016.198
155. Auciello FR, Ross FA, Ikematsu N, Hardie DG. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. FEBS Lett (2014) 588:3361-6. doi:10.1016/j.febslet.2014.07.025
156. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 13:251-62. doi:10.1038/nrm3311
157. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 6:91-9. doi:10.1016/j.ccr.2004.06.007
158. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 106:11137-42. doi:10.1073/pnas.0900465106
159. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2006) 107:2013-21. doi:10.1182/blood-2005-05-1795
160. Dong H, Bullock TNJ. Metabolic influences that regulate dendritic cell function in tumors. Front Immunol (2014) 5:24. doi:10.3389/fimmu.2014.00024
161. Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol (2017) 43:74-89. doi:10.1016/j.semcancer.2017.03.001
162. Hoque R, Farooq A, Ghani A, Gorelick F, Mehal WZ. Lactate reduces liver and pancreatic injury in toll-like receptor-and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity. Gastroenterology (2014) 146:1763-74. doi:10.1053/j.gastro.2014.03.014
163. Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood (1999) 94:2880-9
164. Zhang Z, Liu Q, Che Y, Yuan X, Dai L, Zeng B, et al. Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res (2010) 70:89-98. doi:10.1158/0008-5472.CAN-09-2970
165. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 16:880-6. doi:10.1038/nm.2172
166. Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol (2014) 192:2920-31. doi:10.4049/jimmunol.1302801
167. Coutant F, Agaugué S, Perrin-Cocon L, André P, Lotteau V. Sensing environmental lipids by dendritic cell modulates its function. J Immunol (2004) 172:54-60. doi:10.4049/jimmunol.172.1.54
168. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell (2015) 161:1527-38. doi:10.1016/j.cell.2015.05.025
169. Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res (2017) 77:4684-96. doi:10.1158/0008-5472.CAN-17-0393
170. Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res (2015) 3:254-65. doi:10.1158/2326-6066.CIR-14-0018
171. Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res (2006) 16:213-22. doi:10.1097/01.cmr.0000215030.69823.11
172. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer (2012) 106:1446-52. doi:10.1038/bjc.2012.95
173. Linnemann C, Schildberg FA, Schurich A, Diehl L, Hegenbarth SI, Endl E, et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 128:e728-37. doi:10.1111/j.1365-2567.2009.03075.x
174. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 5:304. doi:10.3389/fimmu.2014.00304
175. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2003) 101:3985-90. doi:10.1182/blood-2002-07-2113
176. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 112:1822-31. doi:10.1182/blood-2008-02-136325
177. Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 74:7250-9. doi:10.1158/0008-5472.CAN-13-3583
178. Cekic C, Kayhan M, Koyas A, Akdemir I, Savas AC. Molecular mechanism for adenosine regulation of dendritic cells. J Immunol (2017) 198(1 Suppl):67.8
179. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity (2017) 46:233-44. doi:10.1016/j.immuni.2017.01.005
180. Galvin KC, Dyck L, Marshall NA, Stefanska AM, Walsh KP, Moran B, et al. Blocking retinoic acid receptor-a enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells. Cancer Immunol Immunother (2013) 62:1273-82. doi:10.1007/s00262-013-1432-8
181. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell (2016) 30:391-403. doi:10.1016/j.ccell.2016.06.025
182. Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, et al. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Cancer Res (2011) 71:6611-20. doi:10.1158/0008-5472.CAN-11-1801
183. Tian S, Liu Z, Donahue C, Falo LD, You Z. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2012) 20:432-42. doi:10.1038/mt.2011.183
184. Zhang Y, Chen G, Liu Z, Tian S, Zhang J, Carey CD, et al. Genetic vaccines to potentiate the effective CD103 + dendritic cell-mediated cross-priming of antitumor immunity. J Immunol (2015) 194:5937-47. doi:10.4049/jimmunol.1500089
185. Su J, Gao T, Jiang M, Wu L, Zeng W, Zhao S, et al. CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma. Oncotarget (2016) 7:64778-84. doi:10.18632/oncotarget.11415
186. Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, et al. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget (2015) 6:32748-60. doi:10.18632/oncotarget.4977
187. Amiel E, Everts B, Fritz D, Beauchamp S, Ge B, Pearce EL, et al. Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function. J Immunol (2014) 193:2821-30. doi:10.4049/jimmunol.1302498
188. Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, et al. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol (2012) 189:2151-8. doi:10.4049/jimmunol.1103741
189. Raïch-Regué D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology (2016) 5:e1146841. doi:10.1080/2162402X.2016.1146841
190. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin (2017) 67:326-44. doi:10.3322/caac.21398
191. Xu C, Ruan B, Jiang Y, Xue T, Wang Z, Lu H, et al. Antibiotics-induced gut microbiota dysbiosis promotes tumor initiation via affecting APC-Th1 development in mice. Biochem Biophys Res Commun (2017) 488:418-24. doi:10.1016/j.bbrc.2017.05.071
192. Cheng M, Qian L, Shen G, Bian G, Xu T, Xu W, et al. Microbiota modulate tumoral immune surveillance in lung through a T17 immune cell-dependent mechanism. Cancer Res (2014) 74:4030-41. doi:10.1158/0008-5472.CAN-13-2462
193. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 117:2197-204. doi:10.1172/JCI32205
194. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 342:967-70. doi:10.1126/science.1240527
195. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 350:1084-9. doi:10.1126/science.aac4255
196. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (2015) 350:1079-84. doi:10.1126/science.aad1329
197. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol (2017) 28:1368-79. doi:10.1093/annonc/mdx108
198. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, et al. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. J Clin Oncol (2017) 35(15 Suppl):3008-3008. doi:10.1200/JCO.2017.35.15_suppl.3008
199. Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia (2017) 19:848-55. doi:10.1016/j.neo.2017.08.004
200. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol (2016) 16:341-52. doi:10.1038/nri.2016.42
201. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer (2017) 17:271-85. doi:10.1038/nrc.2017.13
202. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun (2016) 7:10391. doi:10.1038/ncomms10391
203. Salava A, Aho V, Pereira P, Koskinen K, Paulin L, Auvinen P, et al. Skin microbiome in melanomas and melanocytic nevi. Eur J Dermatol (2016) 26:49-55. doi:10.1684/ejd.2015.2696
204. Chng KR, Tay ASL, Li C, Ng AHQ, Wang J, Suri BK, et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol (2016) 1:16106. doi:10.1038/nmicrobiol.2016.106
205. Ganju P, Nagpal S, Mohammed MH, Nishal Kumar P, Pandey R, Natarajan VT, et al. Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects. Sci Rep (2016) 6:18761. doi:10.1038/srep18761
206. Vujkovic-Cvijin I, Wei M, Restifo NP, Belkaid Y. Role for skin-associated microbiota in development of endogenous anti-melanocyte immunity in vitiligo. J Immunol (2017) 198(1 Suppl):58.14
207. Yang J, Qin Y, Li L, Cao C, Wang Q, Li Q, et al. Apoptotic melanoma B16-F1 cells induced by lidamycin could initiate the antitumor immune response in BABL/c mice. Oncol Res (2016) 23:79-86. doi:10.3727/096504015X14478843952942
208. Son KJ, Choi KR, Ryu CK, Lee SJ, Kim HJ, Lee H. Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative. PLoS One (2017) 12:e0173121. doi:10.1371/journal.pone.0173121
209. Son K, Choi KR, Lee SJ, Lee H. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw (2016) 16:75. doi:10.4110/in.2016.16.1.75
210. Werthmöller N, Frey B, Rückert M, Lotter M, Fietkau R, Gaipl US. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo. Int J Hyperth (2016) 32:23-30. doi:10.3109/02656736.2015.1106011